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The aim of this study was to assess the eﬃcacy of Normast 300mg in reducing swelling and pain after the surgical extraction of
impacted lower third molars. Materials and Methods. A randomized, split-mouth, single-blind study was conducted on 30 patients
between 18 and 30 years of age requiring lower third molar extraction. Patients underwent bilateral extractions in a randomized
sequence, one extraction being performed under Normast treatment. The Normast treatment involved 2 tablets a day for 15
days. The parameters assessed at each procedure were trismus, swelling, pain, NSAID consumption, postoperative complications,
drug tolerability, and safety. The results obtained were processed using repeated measures analysis of variance. Results.P e r c e i v e d
postoperative pain was reportedly signiﬁcantly milder on Normast treatment than control. The trend of the means diﬀered over
time (P<. 0001) and between the two extraction groups (P<. 0221). On the other hand, for edema and trismus, the trend diﬀered
over time for both groups but did not diﬀer between the two groups. Discussion. Our analyses indicate that patients experienced
signiﬁcantly less postoperative pain when they were treated with Normast. Conclusions. Administering Normast improves the
postoperative course—in terms of pain—after lower third molar extraction.
1.Introduction
Thethirdmolars,andthoseofthemandibleinparticular,are
the most frequently impacted of all teeth, with an incidence
ranging between 9.5% and 39%, depending on the source
considered [1].
Impacted third molar extraction is therefore a common
p r o c e d u r ei no r a la n dm a x i l l o f a c i a ls u r g e r y[ 2–10], but
third molar surgery is associated with an incidence of
intraoperative and postoperative complications in the range
of 4.6% to 30.9% [4]. Patients complain of pain, swelling,
andtrismusbeingthefactorsthatmostnegativelyaﬀecttheir
quality of life [3, 11] in the postoperative period.
Most authors prescribe NSAIDs (nonsteroidal anti-inﬂa-
mmatory drugs) to prevent and treat postoperative pain and
glucocorticoids to control edema and trismus [12].
The aim of the present study was to assess the eﬃcacy of
Normast 300mg in reducing postoperative pain and swelling
after surgery to extract impacted lower third molars. Nor-
mast was reported to the Italian Ministry of Public Health as
a“foodproductforspecialmedicinalpurposes,”basedonthe
European Community standards; the product has no known
side eﬀects and is generally well tolerated. The active ingredi-
ent is micronized palmitoylethanolamide (300mg tablets).
Palmitoylethanolamide (PEA) has been proposed as
a substance capable of modulating mast cell response to
inﬂammation [13–15] and might represent a new approach
to the treatment of inﬂammatory processes [16].
PEA is an endogenous endocannabinoid belonging to
the N-ACETYL ETHANOLAMINES (NAE) superfamily
[17, 18].
PEA is a naturally occurring substance isolated from soy
lecithin, egg yolk, and ground peanuts; it is also contained in
the lipid fraction of rat brain, liver, and skeletal muscle. The
presence of PEA has been documented in the brain and bone
marrow of mouse, in dog heart extracts, and in degraded
human tissues and peritoneal macrophages. NAEs are also
containedintheblood.ThereisproofofthepresenceofPEA,
and other NAEs, in marine species as well as in mammals
[18].2 ISRN Surgery
It has been suggested that PEA behaves like an endoge-
nous ligand for the CB2 receptors [17, 18] ,as u b g r o u po f
endocannabinoid receptors that mediate analgesic eﬀects,
and their involvement in painful neuropathic and inﬂam-
matory states has been demonstrated [19]. The literature
suggests that PEA only becomes eﬀective as an analgesic in
the presence of an inﬂammatory state [14], by downregu-
lating mast cell activity in vivo, and thereby reducing tissue
inﬂammation [13, 14, 17].
PEA is a compound with documented antinociceptive
andanti-inﬂammatoryeﬀects[17,18,20],butitalsoinhibits
food intake, reduces gastrointestinal motility, inhibits the
proliferation of cancer cells, and has a neuroprotective action
[17].
The eﬀect of PEA on edema is both dose and time
dependent [15].
2.MaterialsandMethods
A randomized, split-mouth, single-blind study was con-
ducted on patients referred to the Department of Dentistry
at the University of Padua.
The study was conducted in accordance with the ethical
principles for medical research on human beings established
by the 1964 Helsinki protocol.
It was not necessary to obtain the approval of the local
ethical committee because Normast is not registered as a
drug but as a “food product for special medicinal purposes,”
and it is already used in other medical specialties.
2.1. Inclusion and Exclusion Criteria. Thirty patients were
selected, aged between 18 and 30 years, who needed bilateral
lower third molar extractions and who gave their informed
consent to enrolment in the study. On medical examination,
the third molars had to show no signs of inﬂammation or
tooth decay. Each patient’s X-rays had to show that the two
lower third molars were identical in position, orientation,
depth, and class of impaction according to the Pell and
Gregory classiﬁcation.
Patients over 30 years old were ruled out, and so
were patients needing monolateral extractions, individuals
who had taken part in other clinical studies in the two
months prior to enrolment for the present study, patients
with systemic diseases and taking chronic pharmacological
therapy, and cases thought unlikely to assure the necessary
compliance. Patients with known allergies to NSAIDs were
also excluded, as were those who could not take such medi-
cation for other health-related reasons (gastric disorders).
A preoperative clinical examination was conducted on
the oral cavity, obtaining an orthopantomography and,
where necessary, a CT processed using DentaScan [21].
Before proceeding, the whole procedure was explained to
patients in detail and their informed consent was obtained.
Patientswerealsogivenanexplanatoryletterfortheirgeneral
practitioner.
Each of the 30 patients was scheduled to undergo lower
third molar extraction bilaterally, the two extractions being
performed in two separate sessions approximately 30 days
apart. The surgery was always conducted by the same
qualiﬁed operator. In each individual, one extraction was
completed while, on treatment with Normast, the other
beingconsideredasacontrol;theorderofthetwoextractions
was randomly assigned. For the treatment arm, patients had
to take Normast at a dose of 2 tablets a day (one in the
morning and one in the evening) for a period of 15 days (6
days before surgery and 9 days afterwards).
2.2. Assessment Parameters. The following parameters were
recorded:
(i) trismus: mouth opening range was assessed by
measuring the distance between the incisors before
surgery (T0) and on the 3rd and 7th days after
surgery (T1a n dT2) [3];
(ii) swelling: facial edema was assessed by measuring the
distances between the labial commissure and the tra-
gus (following the trend of the cheek), and between
the lateral canthus and the gonion, before surgery
(T0) and on the 3rd and 7th days afterwards (T1
and T2, resp.) [3]; the measurements were obtained
with a silk 2/0 suture thread, which was then placed
againstaruler;toensurereproduciblemeasurements,
thepointsbetweenwhichthemeasurementwastaken
were marked with a felt tip pen;
(iii) pain: the pain perceived by the patient was scored on
avisualanalogscale(VAS)10cmlong,where0meant
no pain and 10 meant the worst pain imaginable [3];
(iv) NSAID consumption in the week after surgery;
(v) postoperative complications;
(vi) drug tolerability and safety: recording any onset of
adverse events at the end of the treatment arm.
On the day scheduled for surgery, in addition to collecting
information concerning trismus, swelling, and pain percep-
tion at T0, an adhoc report form was used to record the
patient’s gender and age, the tooth extracted (3.8 or 4.8),
the class and depth of the tooth according to the Pell and
Gregory classiﬁcation, and its orientation according to the
Winter classiﬁcation, the duration of the procedure, the date
of starting the Normast treatment, and its duration (for
patients in the treatment arm).
ForthedatatorecordatT1(onthe3rddayaftersurgery),
that is, trismus, swelling, and perceived pain, patients were
given an adhoc report form and asked to record these
measurements at home; patients received a telephone call to
remind them to do so.
On the day of their operation, patients were also given
a diary and asked to make an accurate note of any NSAIDs
used during the postoperative period.
On the 7th day after the procedure, patients returned to
the outpatients clinic at the Department of Dentistry to have
their stitches removed, when the measurements relating to
T2 (trismus, swelling, and pain) were recorded as well as
an assessment of healing, postoperative course, and any side
eﬀects of the Normast treatment. Patients also returned the
previously distributed report forms and diaries on the use of
analgesics.ISRN Surgery 3
2.3. Statistical Analysis. The results were processed using
repeated measures analysis of variance and were considered
signiﬁcant when P<. 05.
3. Results
Only 26 of the 30 patients enrolled completed the protocol,
while 4 dropped out as a result of inadequate compliance: 2
forgot to take Normast for the full 15-day period; one failed
to return for the second extraction; one only took Normast
for 3 days, then abandoned the drug, reporting the “onset
of palpitations lasting 2-3 hours approximately an hour after
taking the tablets” (they were apparently taking no other
drugs in combination with the Normast treatment).
The protocol also involved assessing NSAID intake
in the ﬁrst week postoperatively, but the results proved
impossible to analyze statistically because the data were
excessively heterogeneous: although patients had been given
clear instructions on the type of drug to use, only 4 patients
took the prescribed ibuprofen 600mg for postoperative pain
control;theother22spontaneouslyoptedforalternativepain
control drugs (paracetamol, nimesulide, and ketoprofen)
and at highly variable doses.
There were 3 cases of alveolitis, two of which occurred in
the same patient; this would seem to have been a patient-
related complication rather than a drug-related issue. The
ﬁndings for postoperative pain, mouth opening range, the
distance between the lateral canthus and the gonion, and the
distance between the labial commissure and the tragus were
assessed by repeated measures analysis of variance using as
explanatory variables age, gender, side of mouth, duration
of the procedure, time since surgery, and the interaction
between the treatment and the time since surgery. All the
models were amply signiﬁcant.
Theresultsshowedthatthemeansforpostoperativepain,
mouth opening range, and the distance between the labial
commissure and the tragus changed signiﬁcantly with time,
irrespective of the Normast treatment or any of the other
explanatory variables.
The “duration of the procedure” variable was never
statistically signiﬁcant.
For postoperative pain control, the trend of the means
diﬀered over time (P<. 0001) and also between the two
extraction groups (P<. 0221) (see Figure 1).
At T0, all the values recorded on the VAS were nil.
At T1, the mean VAS recorded by the patients taking
Normast was 3.8 ± 3.09cm, while in the control group it was
5.5 ± 2.42cm; likewise, at T2, the mean VAS for the group
on Normast treatment was lower than in the control group
(1.0 ± 1.82cm and 1.5 ± 2.18cm, resp.).
T h et r e n do ft h em e a n sd i ﬀered statistically over time for
mouth opening range too, but it did not diﬀer between the
two extraction groups (see Figure 2); there was evidence of
a signiﬁcant diﬀerence between males and females however
(P<. 0241).
At T0, the mean values were 4.8 ± 0.59cm and 4.7
± 0.71cm for the Normast-treated group and the control
group, respectively.
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Figure 1: Trend of means ± standard errors for the VAS.
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Figure 2: Trend of the means ± standard errors for the mouth
opening range.
At T1, the mean mouth opening range for patients on
Normast treatment was 3.6 ± 2.21cm, as opposed to 3.1 ±
1.18cm for the control group.
At T2, the mean mouth opening range had increased to
4.1 ± 0.89cm for the treated patients and 4.1 ± 0.93cm for
the controls.
None of the variables were signiﬁcant for the distance
between the lateral canthus and the gonion because of the
marked variability of the measurements obtained.
At T0, the mean distance was 9.6 ± 0.91cm and 9.6
± 0.79cm for the Normast-treated and control groups,
respectively.
At T1,thedistancewas9.6 ±1.63cminthetreatedgroup
and 9.8 ± 1.46cm in the control group, and, at T2, the
ﬁgures were 9.7 ± 1.06cm and 9.7 ± 0.86cm, respectively
(see Figure 3).
As for the distance between the labial commissure and
the tragus, the trend of the mean measurements diﬀered
statistically over time (P<. 0058), but not between the two
treatment groups.4 ISRN Surgery
At T0,themeandistanceforthegroupofpatientstreated
with Normast was 10.2 ± 0.74cm, while for the controls it
was 9.9 ± 1.11cm.
At T1, the mean distance was 10.7 ± 1.53cm for the
Normast-treated group and 10.5 ± 1.46cm for the controls,
and, at T2, the ﬁgures were 10.2 ± 1.02cm and 10.3 ±
1.11cm, respectively (see Figure 4).
Two adverse reactions to Normast were reported by
patients, that is, one case of drowsiness and one of palpita-
tions.
4. Discussion
The statistical analysis produced statistically signiﬁcant
results inasmuch as concerns the correlation between the use
of PEA and the perceived postoperative pain, as identiﬁed by
means of a VAS.
As shown in Figure 1, while the baseline value was 0 at
T0 for both groups, the mean score on the VAS at T1a n d
T2 was lower for the Normast treatment arm than for the
control arm of the study.
Concerning trismus, the mean mouth opening range on
the third postoperative day (T1) among the patients treated
with Normast was 0.5cm wider than that in the control
group. Figure 1 shows, however, that the mean values for the
two groups were comparable by postoperative day 7. This
would suggest that Normast is able to improve the early
postoperative course in terms of pain.
Two distances were considered to assess edema, that is,
from the lateral canthus to the gonion and from the labial
commissure to the tragus.
Figure 3 shows that the mean distances between the
lateral canthus and the gonion were similar for the two
groups at T0. Swelling was more severe in the control group
than in the group treated with Normast at T1, then it
gradually decreased up to day 7. The ﬁgure suggests that
patients on Normast treatment suﬀered no edema from T0
to T1, but their swelling increased from the 3rd day onwards
up until the 7th day, and at T2 the mean value was much
the same as in the control group. As reported elsewhere in
the literature [7, 22], this means that swelling in the control
group increased up to the second or third postoperative
day then regressed, disappearing completely between the
5th and 7th days after the extraction. The ﬁgure indicates
that postoperative edema develops under treatment with
Normast too, but its onset is delayed by comparison with the
control group.
Figure 4 shows diﬀerent mean values of distances
between the labial commissure and the tragus for the
Normast-treated and control groups at T0, with a virtually
parallel rising trend up to T1, whereas, from T1t oT2, there
is a faster reduction for the treatment group, which reaches
lower mean values at T2 than in the control group.
Despite the impression given by the corresponding
graphs,itisworthbearinginmindthatthestatisticalanalysis
demonstrated that the trend for edema and trismus varied
over time in both groups, but it did not diﬀer between the
groups.
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Figure 3: Trend of the means ± standard errors for the distance
between the lateral canthus and the gonion.
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Figure 4: Trend of means ± standard errors for the distance
between the labial commissure and the tragus.
As for the adverse events relating to the Normast treat-
ment, one patient reported tachycardia developing about an
hour after taking the tablets (this patient was ruled out of the
study)andoneotherpatientreporteddrowsinessaftertaking
Normast.
The patient with palpitations associated with the use
of Normast reported taking no other drugs at the same
time as the Normast treatment. About a week after being
excluded from the study, the patient was asked to return to
the outpatients clinic at the Department of Dentistry: when
further details were obtained, the patient’s medical history
ultimately proved positive for the use of cannabinoids. There
is nothing in the medical literature on any consequences
of the joint use of natural or synthetic cannabinoids and
PEA, but it may be that the side eﬀects reported by this
patient were the consequence of a synergic eﬀect of PEA and
tetrahydrocannabinol.
5. Conclusions
According to the literature, patients complain of pain,
swelling, and trismus as the main factors negativelyISRN Surgery 5
inﬂuencing their quality of life [3, 11] after surgery for lower
third molar extraction.
The postoperative course is commonly managed by
prescribing NSAIDs to control postoperative pain and
glucocorticoids for trismus and edema.
Our study demonstrated that combining Normast
(palmitoylethanolamide) with the above-mentioned medi-
cation signiﬁcantly reduces perceived pain, as recorded on a
VAS, during the week after the surgical procedure.
For edema and trismus, on the other hand, our statistical
analysis identiﬁed no signiﬁcant diﬀerences between the
extractions with and without associated Normast treatment.
We therefore conclude that, as concerns pain at least,
treatment with Normast improves the postoperative course
after impacted lower third molar extraction.
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